Syndesmophytes are bony growths that form along the spinal ligaments, gradually bridging the gaps between vertebrae. They develop when the tough, fibrous tissue connecting your vertebrae begins to calcify and turn into bone, a process driven by a combination of inflammation, tissue repair, and mechanical stress. Syndesmophytes are a hallmark of ankylosing spondylitis and related forms of inflammatory spinal arthritis, and their progression over time can eventually fuse sections of the spine together.
How Syndesmophytes Form
Your vertebrae are connected by layers of ligaments and a thick ring of fibrous tissue called the annulus fibrosus, which wraps around each spinal disc. In healthy spines, these tissues stay flexible. In people with certain types of inflammatory arthritis, the body’s repair process goes into overdrive. Inflammatory signals trigger bone-building cells to activate in areas where they normally wouldn’t, and the soft connective tissue between vertebrae gradually hardens into bone.
This isn’t a single event. It’s a slow remodeling process involving cycles of cellular growth, maturation, and calcification. The bone formation typically starts at the corners of the vertebral bodies, right where the annulus fibrosus attaches. Over months or years, a thin vertical column of new bone extends upward or downward from one vertebral corner toward the next. When a syndesmophyte from one vertebra meets the one growing from its neighbor, it creates a bony bridge that locks those two vertebrae together.
Conditions That Cause Syndesmophytes
Syndesmophytes are most closely associated with ankylosing spondylitis (AS), a chronic inflammatory disease that primarily targets the spine and sacroiliac joints. In late-stage AS, syndesmophytes can fuse multiple vertebrae into a single rigid column, producing the characteristic “bamboo spine” appearance on X-rays. This term comes from the way the fused vertebrae resemble segments of bamboo stalk, with syndesmophytes forming the vertical connections between them.
Syndesmophytes also occur in other conditions within the spondyloarthritis family, including psoriatic arthritis and reactive arthritis. The type and shape of the syndesmophyte can differ depending on the underlying disease, which helps doctors distinguish between these conditions on imaging.
Marginal vs. Non-Marginal Types
Not all syndesmophytes look the same. Doctors classify them into two main types based on where they originate and how they grow.
- Marginal syndesmophytes are the classic type seen in ankylosing spondylitis. They are thin, vertical growths that rise from the very edge of the vertebral body at an angle close to vertical. They extend neatly from the corner of one vertebra toward the next, forming a fine, slender bridge.
- Non-marginal (paramarginal) syndesmophytes originate away from the edge of the vertebra. They tend to be asymmetrical, thick, bulky, and irregular in shape. This chunky type is more typical of psoriatic arthritis and can look quite different on X-rays, sometimes described as “fluffy” or comma-shaped.
This distinction matters because the type of syndesmophyte visible on imaging can point a doctor toward the correct diagnosis before other tests confirm it.
How Syndesmophytes Differ From Osteophytes
Syndesmophytes are sometimes confused with osteophytes, the bone spurs that develop in ordinary degenerative disc disease (the kind of wear-and-tear arthritis common with aging). The key difference is direction and origin. Osteophytes grow horizontally, jutting outward from the edges of vertebrae like small shelves or lips. Syndesmophytes grow vertically, climbing from one vertebral corner straight up toward the next vertebra. Osteophytes are also typically broader at their base, while marginal syndesmophytes are slim and column-like. Seeing vertical bridging on a spine X-ray is a strong signal that inflammatory arthritis, not simple degeneration, is at work.
Impact on the Spine
The most significant consequence of syndesmophyte growth is progressive loss of spinal flexibility. Each bridging syndesmophyte eliminates movement at that vertebral segment. As more segments fuse, the spine becomes increasingly rigid. People with advanced disease may lose the ability to bend, twist, or look over their shoulder. The forward curvature of the upper back can increase, pulling posture into a fixed, stooped position.
Fusion also changes the mechanical properties of the spine in ways that create new risks. Fused vertebral segments can’t absorb impact the way a flexible spine does, so even minor falls or jolts can cause fractures. Research has shown that the trabecular bone inside fused vertebrae tends to lose density over time, making the bone itself more fragile even as the outer structure appears solidly connected.
How Doctors Track Progression
Syndesmophyte growth is monitored primarily through lateral X-rays of the cervical and lumbar spine. The most widely used measurement tool is the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), which evaluates 24 vertebral corners across the neck and lower back. Each corner receives a score: 0 for no changes, 1 for early signs like erosion or squaring of the vertebral edge, 2 for a syndesmophyte, and 3 for a bridging syndesmophyte that fully connects two vertebrae. The total possible score is 72, representing complete fusion at every measured site.
This scoring system allows doctors to track how quickly bone formation is progressing over time and to evaluate whether treatment is slowing things down. MRI can detect earlier inflammatory changes before bone has formed, but X-rays remain the standard for measuring the structural damage syndesmophytes cause.
Treatment and Slowing Progression
Managing syndesmophytes focuses on controlling the underlying inflammation that drives their formation. Anti-inflammatory medications are a cornerstone of treatment. Biologic therapies that block a key inflammatory protein called TNF have shown the ability to slow spinal bone formation, though this effect takes time to become apparent. Studies suggest it may take at least four years of continuous biologic treatment before a measurable reduction in new syndesmophyte formation shows up on X-rays.
There is also evidence that combining biologics with regular anti-inflammatory medication may offer additional protection. In one clinical trial, new syndesmophytes appeared in 25% of patients on biologic therapy alone compared to 11% of patients who also took a daily anti-inflammatory, though the difference did not reach statistical significance in that study’s sample size. The trend suggests that consistent suppression of inflammation through multiple pathways may be the most effective strategy.
Once a syndesmophyte has fully bridged two vertebrae and fused them together, that structural change is permanent. This is why early diagnosis and treatment matter: the goal is to intervene before significant fusion occurs, preserving as much spinal mobility as possible.